In silico exploration for identifying structure-activity relationship of MEK inhibition and oral bioavailability for isothiazole derivatives

Chemical Biology and Drug Design

Volumn 76, Issue 5, 2010, Pages 397-406

  Melagraki, Georgia ^a   Afantitis, Antreas ^b   Sarimveis, Haralambos ^c   Igglessi Markopoulou, Olga ^c   Koutentis, Panayiotis A ^a   Kollias, George ^d  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b NOVAMECHANICS LTD   (Cyprus)

^c NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^d BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

ADME; In silico screening; Isothiazole; MEK inhibitor; Oral bioavailability; QSAR

Indexed keywords

ISOTHIAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; COMPUTER MODEL; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG STRUCTURE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ALGORITHMS; BIOLOGICAL AVAILABILITY; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTEIN KINASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 78651084814     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.01029.x     Document Type: Article

References (39)

1. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong W.T.E., Chang F., Lehmann B. et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta;1773:1263-1284.
2. Thompson N., Lyons J. (2005) Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol;5:350-356.
3. Montagut C., Settleman J. (2009) Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett;283:125-134.
4. Ramnath N., Adjei A. (2007) Inhibitors of Raf kinase and MEK signaling. Update on Cancer Therapeutics;2:111-118.
5. Wang D., Boerner S.A., Wonkler J.D., LoRusso P.M. (2007) Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta;1773:1248-1255.
6. Chen Z., Kim S.-H., Barbosa S.A., Huynh T., Tortolani D.R., Leavitt K.J., Wei D.D., Manne V., Ricca C.S., Gullo-Brown J., Poss M.A., Vaccaro W., Salvati M.E. (2006) Pyrrolopyridazine MEK inhibitors. Bioorg Med Chem Lett;16:628-632.
7. Sebolt-Leopold J.S., Herrera R. (2004) Targeting the mitogenactivated protein kinase cascade to treat cancer. Nat Rev Cancer;4:937-947.
8. El Abdellaoui H., Varaprasad C.V.N.S., Barawkar D., Chakravarty S., Maderna A., Tam R., Chen H. et al. (2006) Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg Med Chem Lett;16:5561-5566.
9. Clerici F., Gelmi M.L., Pellegrino S., Pocar D. (2007) Chemistry of biologically active isothiazoles. Top Heterocycl Chem;9:179-264.
10. Sheppard G.S., Bouska J.J. (2005) Why optimize cancer drugs for ADMET? Drug Discov Today Ther Strateg;2:343-349.
11. Hall M., Frank E., Holmes G., Pfahringer B., Reutemann P., Witten I.H. (2009) The WEKA Data Mining Software: an update. SIGKDD Explor;11:10-18.
12. Stewart J.J.P. (2007) Optimization of parameters for semiempirical methodsV: modification of NDDOapproximations and application to 70 elements. J Mol Model;13:1173-1213.
13. Stewart J.J.P. (2008) Application of the PM6 method to modeling the solid state. J Mol Model;14:499-535.
14. Melagraki G., Afantitis A., Makridima K., Sarimveis H., Igglessi-Markopoulou O. (2006) Prediction of toxicity using a novel RBF neural network training methodology. J Mol Model;12:297-305.
15. Melagraki G., Afantitis A., Sarimveis H., Koutentis P.A., Igglessi-Markopoulou O., Kollias G. (2009) Predictive QSAR workflow for the in silico identification and screening of novel HDAC inhibitors. Mol Divers;13:301-311.
16. Toropov A.A., Toropova A.P., Benfenati E. (2009) Simplified molecular input line entry system-based optimal descriptors: quantitative structure-activity relationship modeling mutagenicity of nitrated polycyclic aromatic hydrocarbons. Chem Biol Drug Des;73:515-525.
17. Toropov A.A., Toropova A.P., Benfenati E. (2009) QSAR modelling for mutagenic potency of heteroaromatic amines by optimal SMILES-based descriptors. Chem Biol Drug Des;73:301-312.
18. Afantitis A., Melagraki G., Sarimveis H., Koutentis P.A., Igglessi-Markopoulou O., Kollias G. (2010) A combined LS-SVM & MLR QSAR workflow for predicting the inhibition of CXCR3 receptor by quinazolinone analogues. Mol Divers;14:225-235.
19. Cortes C., Vapnik V. (1995) Support vector networks. Mach Learn;20:273-297.
20. Shevade S.K., Keerthi S.S., Bhattacharyya C., Murthy K.R.K. (2000) Improvements to the SMO Algorithm for SVM Regression. IEEE Trans Neural Netw;11:1188-1193.
21. Afantitis A., Melagraki G., Sarimveis H., Koutentis P.A., Markopoulos J., Igglessi-Markopoulou O. (2006) A novel QSAR model for evaluating and predicting the inhibition of dipeptidyl aspartyl fluoromethylketones. QSAR Comb Sci;25:928-935.
22. Afantitis A., Melagraki G., Sarimveis H., Igglessi-Markopoulou O., Kollias G. (2009) A novel QSAR model for predicting the inhibition of CXCR3 receptor by 4-N-aryl-[1,4] diazepane ureas. Eur J Med Chem;44:877-884.
23. Zhang S., Golbraikh A., Oloff S., Kohn H., Tropsha A. (2006) A novel automated lazy learning QSAR (ALL-QSAR) approach: method development, applications, and virtual screening of chemical databases using validated ALL-QSAR Models. J Chem Inf Model;46:1984-1995.
24. Melville J.L., Burke E.K., Hirst J.D. (2009) Machine learning in virtual screening. Comb Chem High Throughput Screen;12:332-343.
25. Melagraki G., Afantitis A., Sarimveis H., Koutentis P.A.,Markopoulos J., Igglessi-Markopoulou O. (2007) Optimization ofBiaryl Piperidine and 4-Amino-2-biarylurea MCH1 receptor antagonists using QSAR modeling, classification techniques andvirtual screening. J Comput Aided Mol Des;20:251-267,DOI: 10.1007/s10822-007-9112-4.
26. Melagraki G., Afantitis A., Sarimveis H., Koutentis P.A., Markopoulos J., Igglessi-Markopoulou O. (2007) Identification of a series of novel derivatives as potent HCV inhibitors by a ligand - based virtual screening optimized procedure. Bioorg Med Chem;15:7237-7247.
27. Todeschini R., Consonni V., Mannhold R. (2000) In: Kubinyi H., Timmerman H., Series editors. Handbook of Molecular Descriptors. Weinheim: Wiley-VCH.
28. Singh J., Shaik B., Singh S., Agrawal V.K., Khadikar P.V., Deeb O., Supuran C.T. (2008) Comparative QSAR study on para-substituted aromatic sulphonamides as CAII inhibitors: information versus topological (distance-based and connectivity) indices. Chem Biol Drug Des;71:244-259.
29. Konstantinova E.V. (2005) On some applications of information indices in chemical graph theory. Electron Notes Discrete Math;21:329-351.
30. Shannon C.E. (1948) A mathematical theory of communication. Bell Syst Tech J;27:379-423.
31. Shannon C.E., Weaver W. (1963) The Mathematical Theory of Communication. Urbana, Illinois: University of Illinois Press.
32. Stahura F.L., Godden J.W., Xue L., Bajorath J. (2000) Distinguishing between natural products and synthetic molecules by descriptor Shannon entropy analysis and binary QSAR calculations. J Chem Inf Comput Sci;40:1245-1252.
33. Bonchev D., Randic M. (2003) Shannon's entropy of proteomic 2D-gel maps. Chem Phys Lett;372:548-552.
34. Godden J.W., Bajorath J. (2007) Analysis of chemical information content using shannon entropy. Rev Comput Chem;23:263-289.
35. Devillers J., Balaban A.T. (1999) Topological Indices and Related Descriptors in QSAR and QSPR. The Netherlands: Gordon and Breach Science Publishers.
36. Christoforou I.C., Koutentis P.A., Rees C.W. (2003) Regiospecific Suzuki coupling of 3,5-dichloroisothiazole-4-carbonitrile. Org Biomol Chem;1:2900-2907.
37. Christoforou I.C., Koutentis P.A. (2006) New regiospecific isothiazole C-C coupling chemistry. Org Biomol Chem;4:3681-3693.
38. Christoforou I.C., Koutentis P.A. (2007) 3,4,5-triarylisothiazoles via C-C coupling chemistry. Org Biomol Chem;5:1381-1390.
39. Ioannidou H.A., Koutentis P.A. (2009) The conversion of isothiazoles into pyrazoles using hydrazine. Tetrahedron;65:7023-7037.